Are you Dr. Molldrem?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 102 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Jeffrey Molldrem, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and California. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1993 - 1996
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1990 - 1993
University of Minnesota Medical SchoolClass of 1990
Certifications & Licensure
CA State Medical License 1993 - Present
FL State Medical License 2021 - Present
TX State Medical License 1999 - 2025
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2009
Publications & Presentations
PubMed
- Unlocking Intracellular Oncology Targets: The Unique Role of Antibody-Based T-Cell Receptor Mimic (TCRm) Therapeutics in T-Cell Engagers (TCEs) and Antibody-Drug Conju...Jeffrey Molldrem, Dongxing Zha
Cancers. 2024-11-08 - Hu8F4-CAR T cells with mutated Fc spacer segment improve target specificity and mediate anti-leukemia activity in vivo.Hong He, Rolando A Vedia, Sijie Lu, Qiaochuan Li, Kathryn R Cox
Cytotherapy. 2024-11-01 - 1 citationsBacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease.Eiko Hayase, Tomo Hayase, Akash Mukherjee, Stuart C Stinson, Mohamed A Jamal
Cell Host & Microbe. 2024-09-11
Press Mentions
MD Anderson Cancer Center Gets $5.7M for Leukemia ResearchMay 16th, 2023- NEI Scientists Publish Recipe for Making Blood Vessel Cells from Patient Stem CellsMay 15th, 2023
Making Cancer History®: Free Seminar Comes to AustinAugust 11th, 2016- Join now to see all
Grant Support
- Adoptive Cellular Therapy For Myeloid LeukemiaNational Cancer Institute2008–2011
- Proteinase 3-Derived Peptide Epitopes To Elicit Cytotoxic T Lymphocytes TargetingNational Cancer Institute2005–2009
- Immunotherapy Of Low Risk Myelodysplastic SyndromeNational Cancer Institute2001–2005
- Proteinase 3 Specific Immunotherapy Of LeukemiaNational Cancer Institute1999–2002
